Base de dados : MEDLINE
Pesquisa : C01.252.400 [Categoria DeCS]
Referências encontradas : 10641 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1065 ir para página                         

  1 / 10641 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29376609
[Au] Autor:Chubukova OA; Shkarin VV
[Ad] Endereço:Nizhny Novgorod State Medical Academy of Minzdrav of Russia, Nizhny Novgorod, Russia.
[Ti] Título:[Concomitant urogenital infections in men].
[So] Source:Urologiia;(6):126-130, 2017 Dec.
[Is] ISSN:1728-2985
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:The article presents possible combinations of urogenital infections of various etiologies and some pathogenetic, clinical and epidemiological features, and issues of epidemiological surveillance for co-infection. The authors describe in detail combinations with each other and with other diseases of such pathogens as Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma spp., Neisseria gonorrhoeae, Trichomonas vaginalis. They also focus on the problem of co-occurrence of human papillomavirus (HPV) with other urogenital pathogens. The article raises the question of the need to introduce new scientific data on the epidemiology of concomitant urogenital infections in men in the practice of diagnosis, treatment, registration, and implementation of preventive and anti-epidemic measures.
[Mh] Termos MeSH primário: Coinfecção
Infecções por Bactérias Gram-Negativas
Infecções por Papillomavirus
Infecções Urinárias
[Mh] Termos MeSH secundário: Coinfecção/diagnóstico
Coinfecção/microbiologia
Coinfecção/terapia
Coinfecção/virologia
Infecções por Bactérias Gram-Negativas/diagnóstico
Infecções por Bactérias Gram-Negativas/microbiologia
Infecções por Bactérias Gram-Negativas/terapia
Infecções por Bactérias Gram-Negativas/virologia
Seres Humanos
Masculino
Infecções por Papillomavirus/diagnóstico
Infecções por Papillomavirus/microbiologia
Infecções por Papillomavirus/terapia
Infecções Urinárias/diagnóstico
Infecções Urinárias/microbiologia
Infecções Urinárias/terapia
Infecções Urinárias/virologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE


  2 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453633
[Au] Autor:Ehrmann E; Jolivet-Gougeon A; Bonnaure-Mallet M; Fosse T
[Ad] Endereço:Pôle odontologie, CHU de Nice, Nice, France.
[Ti] Título:Role of DNA gyrase and topoisomerase IV mutations in fluoroquinolone resistance of Capnocytophaga spp. clinical isolates and laboratory mutants.
[So] Source:J Antimicrob Chemother;72(8):2208-2212, 2017 Aug 01.
[Is] ISSN:1460-2091
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: Capnocytophaga spp. are often reported to cause bacteraemia and extra-oral infections and are characterized by their significant contribution to resistance to ß-lactam and macrolide-lincosamide-streptogramin antibiotics in the human oral microbiota. The implication of mutations in the quinolone resistance-determining region (QRDR) of DNA gyrase A and B ( gyrA and gyrB ) and topoisomerase IV ( parC and parE ) of fluoroquinolone (FQ)-resistant Capnocytophaga spp., hitherto unknown, was explored in this study. Methods: Two reference strains ( Capnocytophaga gingivalis ATCC 33624 and Capnocytophaga sputigena ATCC 33612) and four Capnocytophaga spp. isolated from clinical samples were studied. Nine in vitro FQ-resistant mutants, derived from two reference strains and one FQ-susceptible clinical isolate, were selected by successive inoculations onto medium containing levofloxacin. MICs of ofloxacin, norfloxacin, ciprofloxacin, levofloxacin and moxifloxacin were determined. The presumed QRDRs of GyrA, GyrB, ParC and ParE from Capnocytophaga spp. were determined by sequence homology to Bacteroides fragilis and Escherichia coli . PCR primers were designed to amplify the presumed QRDR genetic region of Capnocytophaga spp. and sequence analyses were performed using the BLAST program at the National Center for Biotechnology Information. Results and conclusions: gyrA mutations leading to a substitution from amino acid position 80 to 86 were systematically detected in Capnocytophaga spp. with ciprofloxacin MIC >1 mg/L and considered as the primary target of FQs. No mutational alteration in the QRDR of gyrB was detected. Other mutations in parC and parE led to spontaneous amino acid substitutions of DNA topoisomerase IV subunit B with no alteration in FQ susceptibility.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Capnocytophaga/efeitos dos fármacos
Capnocytophaga/enzimologia
DNA Girase/genética
DNA Topoisomerase IV/genética
Fluoroquinolonas/farmacologia
Mutação de Sentido Incorreto
[Mh] Termos MeSH secundário: Substituição de Aminoácidos
Capnocytophaga/genética
Capnocytophaga/isolamento & purificação
Infecções por Bactérias Gram-Negativas/microbiologia
Seres Humanos
Testes de Sensibilidade Microbiana
Reação em Cadeia da Polimerase
Análise de Sequência de DNA
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Fluoroquinolones); EC 5.99.1.- (DNA Topoisomerase IV); EC 5.99.1.3 (DNA Gyrase)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/jac/dkx119


  3 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29422757
[Au] Autor:Varshney A; Das M; Chaudhary P; Kumari R; Yadav K
[Ad] Endereço:Department of Vitreoretina, C. L. Gupta Eye Institute, Moradabad, Uttar Pradesh, India.
[Ti] Título: as a Causative Agent for Postoperative Endophthalmitis.
[So] Source:Middle East Afr J Ophthalmol;24(4):213-215, 2017 Oct-Dec.
[Is] ISSN:0975-1599
[Cp] País de publicação:India
[La] Idioma:eng
[Ab] Resumo:We report a case of a 55-year-old female who presented with pain, redness, and profound visual loss in her right eye 2 weeks after cataract surgery. An ophthalmic examination showed light perception vision, corneal edema with severe anterior chamber reaction and hypopyon, exudative membranes on the anterior lens surface, and dense vitreous exudates. Under the impression of acute postoperative exogenous endophthalmitis, immediate pars plana vitrectomy with culture of vitreous aspirate and intravitreal antibiotic injections were performed. Bacterial growth was observed on culture plates and broths which were identified as by VITEK 2 compact system. So far, no report has been published regarding endophthalmitis due to . Here, we present the first report of isolated from the ocular specimen.
[Mh] Termos MeSH primário: Aeromonas salmonicida/isolamento & purificação
Endoftalmite/microbiologia
Infecções Oculares Bacterianas/microbiologia
Infecções por Bactérias Gram-Negativas/microbiologia
Complicações Pós-Operatórias
[Mh] Termos MeSH secundário: Amicacina/uso terapêutico
Antibacterianos/uso terapêutico
Extração de Catarata
Dexametasona/uso terapêutico
Quimioterapia Combinada
Endoftalmite/diagnóstico
Endoftalmite/tratamento farmacológico
Infecções Oculares Bacterianas/diagnóstico
Infecções Oculares Bacterianas/tratamento farmacológico
Feminino
Glucocorticoides/uso terapêutico
Infecções por Bactérias Gram-Negativas/diagnóstico
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Seres Humanos
Injeções Intravítreas
Implante de Lente Intraocular
Meia-Idade
Acuidade Visual/fisiologia
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Glucocorticoids); 7S5I7G3JQL (Dexamethasone); 84319SGC3C (Amikacin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE
[do] DOI:10.4103/meajo.MEAJO_238_17


  4 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29318906
[Au] Autor:Choi JJ; McCarthy MW
[Ad] Endereço:a Department of Medicine , Weill Cornell Medical College , New York , NY , USA.
[Ti] Título:Cefiderocol: a novel siderophore cephalosporin.
[So] Source:Expert Opin Investig Drugs;27(2):193-197, 2018 Feb.
[Is] ISSN:1744-7658
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: The emergence of multidrug-resistant bacterial pathogens has led to a global public health emergency and novel therapeutic options and drug-delivery systems are urgently needed. Cefiderocol is a siderophore cephalosporin antibiotic that has recently been developed to combat a variety of bacterial pathogens, including ß-lactam- and carbapenem-resistant organisms. Areas covered: This paper provides an overview of the mutational and plasmid-mediated mechanisms of ß-lactam and carbapenem resistance, the biochemical pathways of siderophores in bacterial iron metabolism, and how cefiderocol may be able to provide better targeted antimicrobial therapy that escape these drug-resistant mechanisms. We also explore the pharmacokinetics of this new compound as well as results from preclinical and clinical studies. Expert opinion: There is an urgent need for novel antimicrobial agents to address the emergence of multidrug-resistant pathogens, which are an increasing cause of morbidity and mortality worldwide. Our understanding of multidrug-resistance and bacterial biochemical pathways continues to expand, and the development of cefiderocol specifically targeting siderophore-mediated iron transport shows potential in escaping mechanisms of drug resistance. Cefiderocol, which demonstrates a favorable side effect profile, has the potential to become first-line therapy for our most aggressive and lethal multidrug-resistant Gram-negative pathogens.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Cefalosporinas/farmacologia
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Cefalosporinas/administração & dosagem
Cefalosporinas/efeitos adversos
Sistemas de Liberação de Medicamentos
Desenho de Drogas
Farmacorresistência Bacteriana Múltipla
Bactérias Gram-Negativas/efeitos dos fármacos
Infecções por Bactérias Gram-Negativas/microbiologia
Seres Humanos
Sideróforos/administração & dosagem
Sideróforos/efeitos adversos
Sideróforos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Cephalosporins); 0 (Siderophores); 0 (cefiderocol)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1080/13543784.2018.1426745


  5 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449953
[Au] Autor:Rezende TFT; Doi AM; Quiles MG; Pignatari ACC; Manfrendi S; Grothe C; Taminato M; Barbosa DA
[Ad] Endereço:Special Clinical Microbiology Laboratory (LEMC/ALERTA), Federal University of São Paulo/UNIFESP/Brazil, São Paulo, Brazil. Electronic address: thaisftr_@hotmail.com.
[Ti] Título:Detection of colonization by carbapenem-resistant organisms by real-time polymerase chain reaction from rectal swabs in patients with chronic renal disease.
[So] Source:J Hosp Infect;96(2):123-128, 2017 Jun.
[Is] ISSN:1532-2939
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Carbapenem-resistant organism (CRO) colonization is a serious problem that increases the risk of infection and contributes to dissemination of antimicrobial resistance in healthcare-associated environments. The risk of acquisition and dissemination of CRO is high in chronic renal failure patients and the surveillance culture is recommended as a component of infection control programmes. AIM: To assess colonization by CRO, comparing phenotypic and molecular-based methods of diagnostics, in rectal swabs in a large population of chronic renal failure patients. METHODS: A total of 1092 rectal swabs (ESwab™) were collected at two different times from 546 chronic kidney disease (CKD) patients from a specialized tertiary care university centre. They were divided into three groups: conservative treatment (N = 129), dialysis (N = 217), and transplanted patients (N = 200). A chromogenic (CHROMagar™) KPC agar and the multiplex real-time polymerase chain reaction (qPCR) targeting carbapenemase-encoding genes were tested as phenotypic and molecular screening for carbapenemase production. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and conventional PCR were also performed on the isolates grown on chromogenic agar. FINDINGS: Among the 1092 samples, 150 (13.7%) were identified as CRO producers according to chromogenic agar. Only 26 (2.4%) were confirmed as KPC by conventional PCR. According to qPCR direct from swab, 31 (2.8%) were positive for KPC, 39 (3.6%) for GES, and three (0.3%) for SPM with kappa index of 0.256. CONCLUSION: The qPCR technique provides faster results when compared to culture method and enables rapid implementation of control measures and interventions to reduce the spread of CRO in healthcare settings, especially among CKD patients.
[Mh] Termos MeSH primário: Proteínas de Bactérias/genética
Bactérias Gram-Negativas/isolamento & purificação
Infecções por Bactérias Gram-Negativas/diagnóstico
Reação em Cadeia da Polimerase em Tempo Real/métodos
Reto/microbiologia
Insuficiência Renal Crônica/complicações
Resistência beta-Lactâmica
beta-Lactamases/genética
[Mh] Termos MeSH secundário: Proteínas de Bactérias/análise
Técnicas Bacteriológicas/métodos
Portador Sadio/diagnóstico
Portador Sadio/microbiologia
Infecções por Bactérias Gram-Negativas/microbiologia
Hospitais Universitários
Seres Humanos
Técnicas de Diagnóstico Molecular/métodos
Fatores de Tempo
beta-Lactamases/análise
[Pt] Tipo de publicação:COMPARATIVE STUDY; EVALUATION STUDIES; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bacterial Proteins); EC 3.5.2.6 (beta-Lactamases); EC 3.5.2.6 (carbapenemase)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180214
[Lr] Data última revisão:
180214
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE


  6 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28466666
[Au] Autor:Irani P; Salimi T; Epstein R; Leone-Perkins M; Aubert R; Khalid M; Epstein E; Teagarden JR
[Ad] Endereço:a AstraZeneca , Luton, Bedfordshire , UK.
[Ti] Título:European and Russian physician awareness of best management approaches for infections due to antibiotic-resistant Gram-negative bacteria.
[So] Source:Curr Med Res Opin;33(8):1467-1472, 2017 Aug.
[Is] ISSN:1473-4877
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: The rapid spread of infections due to antibiotic-resistant, Gram-negative bacteria in Europe and surrounding regions requires a heightened level of awareness among physicians within their practice settings. METHODS: We surveyed 800 physicians who treat these infections across France, Germany, Spain, Italy, and Russia to assess their awareness of best management approaches. RESULTS: We found that more than two-thirds do not consider themselves highly aware of best management practices. The respondents are facing these resistant infections as evidenced by the antibiotics they report using and their stated interest in newer agents. Respondents indicated that precious time is lost waiting for culture results, but also said they will need more information about accuracy, use, and costs for adopting rapid molecular testing. CONCLUSIONS: The survey further identified the need for treatment guidelines and clinical decision support tools that can be applied at the bedside.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Conhecimentos, Atitudes e Prática em Saúde
Médicos/estatística & dados numéricos
[Mh] Termos MeSH secundário: Europa (Continente)
Bactérias Gram-Negativas/efeitos dos fármacos
Seres Humanos
Federação Russa
Inquéritos e Questionários
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1080/03007995.2017.1325731


  7 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27771978
[Au] Autor:Schreiber MP; Shorr AF
[Ad] Endereço:a Department of Internal Medicine , Section of Pulmonary Disease & Critical Care , 110 Irving St NW, Washington , DC , USA.
[Ti] Título:Challenges and opportunities in the treatment of ventilator-associated pneumonia.
[So] Source:Expert Rev Anti Infect Ther;15(1):23-32, 2017 01.
[Is] ISSN:1744-8336
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: Ventilator-associated pneumonia (VAP) is a distinct clinical entity characterized by an onset after 48 hours of the application of mechanical ventilation (MV). Protocols exist to aid in the prevention of VAP, but this infection carries a devastating impact on patient morbidity and potentially mortality. Areas covered: In this review we present key concepts from existing guidelines to aid clinicians. Challenges remain in defining this disease and, most importantly appropriate empiric antimicrobial treatment is the main determinant of outcome. We highlight that the selection of initial antibiotics is critical, as VAP can by caused by a broad array of drug resistant organisms (DROs), the appropriate duration of treatment for VAP is an evolving concept, but may, in part, be guided by biomarkers, and provide focus on diagnostic challenges, initial therapies and treatment strategies for VAP. Both traditional and novel antimicrobials are presented, including developments in the modes of delivery. Expert commentary: The clinical approach to VAP continues to evolve. Recent evidence regarding the changes in microbiology, diagnostics approaches, and treatment strategies for VAP are important for clinicians to remain informed of to provide optimal patient care.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Cuidados Críticos/métodos
Pneumopatias Fúngicas/tratamento farmacológico
Pneumonia Bacteriana/tratamento farmacológico
Pneumonia Associada à Ventilação Mecânica/diagnóstico
Pneumonia Associada à Ventilação Mecânica/tratamento farmacológico
[Mh] Termos MeSH secundário: Antibacterianos/administração & dosagem
Antibacterianos/efeitos adversos
Infecções por Bactérias Gram-Negativas/diagnóstico
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Infecções por Bactérias Gram-Negativas/microbiologia
Infecções por Bactérias Gram-Negativas/mortalidade
Infecções por Bactérias Gram-Positivas/diagnóstico
Infecções por Bactérias Gram-Positivas/tratamento farmacológico
Infecções por Bactérias Gram-Positivas/microbiologia
Seres Humanos
Pneumopatias Fúngicas/diagnóstico
Pneumopatias Fúngicas/microbiologia
Pneumopatias Fúngicas/mortalidade
Pneumonia Bacteriana/diagnóstico
Pneumonia Bacteriana/microbiologia
Pneumonia Bacteriana/mortalidade
Pneumonia Associada à Ventilação Mecânica/microbiologia
Pneumonia Associada à Ventilação Mecânica/mortalidade
Guias de Prática Clínica como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Bacterial Agents)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161101
[St] Status:MEDLINE


  8 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29324785
[Au] Autor:Joerling J; Barth SA; Schlez K; Willems H; Herbst W; Ewers C
[Ad] Endereço:Institute of Hygiene and Infectious Diseases of Animals, Justus Liebig University Giessen, Giessen, Germany.
[Ti] Título:Phylogenetic diversity, antimicrobial susceptibility and virulence gene profiles of Brachyspira hyodysenteriae isolates from pigs in Germany.
[So] Source:PLoS One;13(1):e0190928, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Swine dysentery (SD) is an economically important diarrheal disease in pigs caused by different strongly hemolytic Brachyspira (B.) species, such as B. hyodysenteriae, B. suanatina and B. hampsonii. Possible associations of epidemiologic data, such as multilocus sequence types (STs) to virulence gene profiles and antimicrobial susceptibility are rather scarce, particularly for B. hyodysenteriae isolates from Germany. In this study, B. hyodysenteriae (n = 116) isolated from diarrheic pigs between 1990 and 2016 in Germany were investigated for their STs, susceptibility to the major drugs used for treatment of SD (tiamulin and valnemulin) and genes that were previously linked with virulence and encode for hemolysins (tlyA, tlyB, tlyC, hlyA, BHWA1_RS02885, BHWA1_RS09085, BHWA1_RS04705, and BHWA1_RS02195), outer membrane proteins (OMPs) (bhlp16, bhlp17.6, bhlp29.7, bhmp39f, and bhmp39h) as well as iron acquisition factors (ftnA and bitC). Multilocus sequence typing (MLST) revealed that 79.4% of the isolates belonged to only three STs, namely ST52 (41.4%), ST8 (12.1%), and ST112 (25.9%) which have been observed in other European countries before. Another 24 isolates belonged to twelve new STs (ST113-118, ST120-123, ST131, and ST193). The temporal distribution of STs revealed the presence of new STs as well as the regular presence of ST52 over three decades (1990s-2000s). The proportion of strains that showed resistance to both tiamulin und valnemulin (39.1%) varied considerably among the most frequent STs ranging from 0% (0/14 isolates resistant) in ST8 isolates to 46.7% (14/30), 52.1% (25/48), and 85.7% (6/7) in isolates belonging to ST112, ST52, and ST114, respectively. All hemolysin genes as well as the iron-related gene ftnA and the OMP gene bhlp29.7 were regularly present in the isolates, while the OMP genes bhlp17.6 and bhmp39h could not be detected. Sequence analysis of hemolysin genes of selected isolates revealed co-evolution of tlyB, BHWA1_RS02885, BHWA1_RS09085, and BHWA1_RS02195 with the core genome and suggested independent evolution of tlyA, tlyC, and hlyA. Our data indicate that in Germany, swine dysentery might be caused by a limited number of B. hyodysenteriae clonal groups. Major STs (ST8, ST52, and ST112) are shared with other countries in Europe suggesting a possible role of the European intra-Community trade of pigs in the dissemination of certain clones. The identification of several novel STs, some of which are single or double locus variants of ST52, may on the other hand hint towards an ongoing diversification of the pathogen in the studied area. The linkage of pleuromutilin susceptibility and sequence type of an isolate might reflect a clonal expansion of the underlying resistance mechanism, namely mutations in the ribosomal RNA genes. A linkage between single virulence-associated genes (VAGs) or even VAG patterns and the phylogenetic background of the isolates could not be established, since almost all VAGs were regularly present in the isolates.
[Mh] Termos MeSH primário: Antibacterianos/farmacologia
Brachyspira hyodysenteriae/efeitos dos fármacos
Brachyspira hyodysenteriae/patogenicidade
Farmacorresistência Bacteriana/genética
[Mh] Termos MeSH secundário: Animais
Proteínas de Bactérias/genética
Brachyspira hyodysenteriae/genética
Brachyspira hyodysenteriae/isolamento & purificação
Diterpenos/farmacologia
Disenteria/microbiologia
Disenteria/veterinária
Fezes/microbiologia
Alemanha
Infecções por Bactérias Gram-Negativas/microbiologia
Infecções por Bactérias Gram-Negativas/veterinária
Proteínas Hemolisinas/genética
Filogenia
Polimorfismo de Nucleotídeo Único
Proteínas Ribossômicas/genética
Sus scrofa
Suínos
Doenças dos Suínos/microbiologia
Virulência/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Proteins); 0 (Diterpenes); 0 (Hemolysin Proteins); 0 (Ribosomal Proteins); 0 (ribosomal protein L3); 125-65-5 (pleuromutilin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180112
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190928


  9 / 10641 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29265997
[Au] Autor:Dépret F; Aubry A; Fournier A; Charles-Nelson A; Katsahian S; Compain F; Mainardi JL; Fernandez-Gerlinger MP
[Ad] Endereço:1​Service de Microbiologie, Unité Mobile de Microbiologie Clinique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
[Ti] Título:ß LACTA testing may not improve treatment decisions made with MALDI-TOF MS-informed antimicrobial stewardship advice for patients with Gram-negative bacteraemia: a prospective comparative study.
[So] Source:J Med Microbiol;67(2):183-189, 2018 Feb.
[Is] ISSN:1473-5644
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: The aim of this study was to assess if use of the ß LACTA test (BLT) for extended-spectrum beta-lactamase (ESBL) detection and/or early bacterial identification by mass spectrometry (MALDI-TOF MS) improves therapeutic decision-making when combined with advice from the antimicrobial stewardship team (AMST) for the management of Gram-negative bacillary (GNB) bacteraemia. METHODS: Prospective observational theoretical study that included patients with GNB bacteraemia during a 6-month period. We compared, against the antimicrobial choice of the local AMST as informed of the Gram-stain result, a hypothetical choice, i.e. one AMST would have made had it been informed of the MALDI-TOF MS results only (option H) with the actual choice AMST made after being informed of the combined MALDI-TOF MS and BLT results (option A).Results/Key findings. A total of 131 episodes of GNB bacteraemia were included. Options H and A led to virtually the same rate of efficient antimicrobial therapy (in 120/131 and 123/131 episodes, respectively, P=0.63). Compared to the gold standard, options H and A did not lead to a significant reduction of carbapenem prescription (9/131, 6/131 and 12/131, P=0.57 and P=0.65, respectively). CONCLUSIONS: Under our test conditions, BLT, when used in conjunction with MALDI-TOF MS and AMST advice, did not allow a significant optimization of the antimicrobial prescription made on the basis AMST advice only. However, the impact of BLT should be evaluated in a population with high prevalence of ESBL-producing Enterobacteriaceae and/or when treatment choices are not made by infectious disease specialists.
[Mh] Termos MeSH primário: Antibacterianos/uso terapêutico
Gestão de Antimicrobianos
Bacteriemia/tratamento farmacológico
Tomada de Decisão Clínica
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
beta-Lactamases/análise
[Mh] Termos MeSH secundário: Idoso
Bacteriemia/diagnóstico
Bacteriemia/microbiologia
Carbapenêmicos/uso terapêutico
Feminino
Infecções por Bactérias Gram-Negativas/diagnóstico
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Espectrometria de Massas por Ionização e Dessorção a Laser Assistida por Matriz/métodos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Carbapenems); EC 3.5.2.6 (beta-Lactamases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE
[do] DOI:10.1099/jmm.0.000665


  10 / 10641 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28467715
[Au] Autor:Boags A; Hsu PC; Samsudin F; Bond PJ; Khalid S
[Ad] Endereço:School of Chemistry, University of Southampton , Southampton, United Kingdom , SO17 1BJ.
[Ti] Título:Progress in Molecular Dynamics Simulations of Gram-Negative Bacterial Cell Envelopes.
[So] Source:J Phys Chem Lett;8(11):2513-2518, 2017 Jun 01.
[Is] ISSN:1948-7185
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bacteria are protected by complex molecular architectures known as the cell envelope. The cell envelope is composed of regions with distinct chemical compositions and physical properties, namely, membranes and a cell wall. To develop novel antibiotics to combat pathogenic bacteria, molecular level knowledge of the structure, dynamics, and interplay between the chemical components of the cell envelope that surrounds bacterial cells is imperative. In addition, conserved molecular patterns associated with the bacterial envelope are recognized by receptors as part of the mammalian defensive response to infection, and an improved understanding of bacteria-host interactions would facilitate the search for novel immunotherapeutics. This Perspective introduces an emerging area of computational biology: multiscale molecular dynamics simulations of chemically complex models of bacterial lipids and membranes. We discuss progress to date, and identify areas for future development that will enable the study of aspects of the membrane components that are as yet unexplored by computational methods.
[Mh] Termos MeSH primário: Antibacterianos
Proteínas da Membrana Bacteriana Externa/química
Membrana Celular/química
Bactérias Gram-Negativas
Simulação de Dinâmica Molecular
[Mh] Termos MeSH secundário: Parede Celular
Infecções por Bactérias Gram-Negativas/tratamento farmacológico
Modelos Moleculares
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Bacterial Agents); 0 (Bacterial Outer Membrane Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1021/acs.jpclett.7b00473



página 1 de 1065 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde